Trending Now
Stealth BioTherapeutics Corp (NASDAQ: MITO) Receives Orphan Drug Designation for Elamipretide
Stealth BioTherapeutics Corp (NASDAQ: MITO) announced that it had received Orphan Drug Designation for elamipretide from the FDA. This drug treats Friedreich's ataxia.
The company...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
ADMA Biologics Inc. (NASDAQ:ADMA) Announces Revenue Of $10.3 Million Q3 2020...
ADMA Biologics Inc. (NASDAQ:ADMA) has reported its Q3 financial results and total revenue of $28.3 million for the nine months ended September 2020. The...
MAKE IT MODERN
LATEST REVIEWS
Aikido Pharma Inc (NASDAQ:AIKI) Is Jubilant With Several Antiviral Compounds To...
Aikido Pharma Inc (NASDAQ:AIKI) is pleased with the potential of its broad-spectrum antiviral compounds to cure Ebola, coronavirus, influenza, and other viral infections. It...
MAKE IT MODERN
PERFORMANCE TRAINING
Invesco QQQ Trust Series 1 (QQQ) surges giving bulls a psychological boost
The market was in risk off mode yesterday, but the buyers have stepped back in this morning in the QQQ’s. I don’t...
Vaxart Inc. (NASDAQ: VXRT) says it Has Raised Gross Proceeds of About $90M Through...
Vaxart Inc. (NASDAQ:VXRT) will be able to smoothly continue with the clinical and preclinical development of its product candidates. This will be facilitated by...
Is TSLA stock heading back to the 300 level ?
Investors have regained interest in the tech sector, which was one of the worst-performing sectors in 2022. The tech-heavy Nasdaq Composite has...
Results from PRO2TECT Global Phase 3 Program of Vadadustat Were Top-Line; Akebia Therapeutics Inc...
Akebia Therapeutics Inc (NASDAQ:AKBA) has put in a lot of tenacity and innovation in developing novel therapeutics for people living with kidney disease. Over...
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) Announces Q3 2021 Financial Results Boosted By ARCALYST Revenue...
Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) has announced its Q3 2021 financial results and highlighted its recent portfolio execution.
Kiniksa generated revenue of $12.1 million from...
MAKE IT MODERN
